BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Pharm Country

  Therap’s Medication Administration Tool Can Assist in Reducing Medication Errors

  Therap’s reporting tools are used by Registered Nurses, LPNs, and other caregivers for minimizing medication errors. Therap’s certified electronic health record software is used widely by nurses working at agencies that support individuals with intellectual and developmental disabilities.

  December 2, 2018

   · 

  2 min read
• Pharm Country

  Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies

  Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta® (eltrombopag), compared to other second-line therapies.

  December 2, 2018

   · 

  12 min read
• Drug Development

  Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting

  Maintenance Therapy with NINLARO™ (ixazomib) Improved Progression-Free Survival in Adult Patients with Multiple Myeloma Following Autologous Stem Cell Transplant

  December 2, 2018

   · 

  13 min read
• Drug Development

  Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting

  Harpoon’s Third Product Candidate is Slated for Clinical Development in 2019

  December 2, 2018

   · 

  3 min read
• Drug Development

  Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R2) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

  Pivotal phase 3 data show investigational R2 significantly extended progression-free survival compared with rituximab plus placebo

  December 2, 2018

   · 

  18 min read
• Policy

  European Medicines Agency Accepts Extension Marketing Authorisation Application for Review of Celltrion’s Remsima SC, the Subcutaneous Version of Remsima®

  European Medicines Agency started to officially review ‘Remsima SC’; expecting European approval in the second half of next year

  December 2, 2018

   · 

  2 min read
• Drug Development

  Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs Demonstrating Potent Stem Cell Depletion and Anti-Leukemia Survival Benefit

  Magenta Therapeutics today announced that the Company presented preclinical research on its targeted conditioning programs at the 60th annual meeting of the American Society of Hematology (ASH).

  December 2, 2018

   · 

  9 min read
• BioForest

  Finnish Blood Testing Scale-up and Health Service Provider Introduce Healthcare for the 21st Century - Connecting Molecular Medicine With Lifestyle Habits

  The new service, Virta 360, connects a person’s current state of physical health with their lifestyle. The service helps people to understand their current risks for chronic diseases and identifies potential areas where they can improve their wellbeing.

  December 2, 2018

   · 

  3 min read
• Drug Development

  Magenta Therapeutics Presents New Data from Phase 2 Study of MGTA-456 Cell Therapy in Patients with Inherited Metabolic Disorders

  All five patients with inherited metabolic disorders (IMDs) treated with MGTA-456 in ongoing Phase 2 study met the primary endpoint of successful engraftment

  December 2, 2018

   · 

  9 min read